Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer

Despite effective strategies, resistance (R) in HER2+ breast cancer (BC) remains a challenge. While the Mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2+ models, its potential role in resistance to HER2-targeted therapy is unknown. Parental HER2+ BC cells...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Res
Main Authors: Sethunath, Vidyalakshmi, Hu, Huizhong, Angelis, Carmine De, Veeraraghavan, Jamunarani, Qin, Lanfang, Wang, Nicholas, Simon, Lukas M., Wang, Tao, Fu, Xiaoyong, Nardone, Agostina, Pereira, Resel, Nanda, Sarmistha, Griffith, Obi L., Tsimelzon, Anna, Shaw, Chad, Chamness, Gary C., Reis-Filho, Jorge S., Weigelt, Britta, Heiser, Laura M., Hilsenbeck, Susan G., Huang, Shixia, Rimawi, Mothaffar F., Gray, Joe W., Osborne, C. Kent, Schiff, Rachel
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825570/
https://ncbi.nlm.nih.gov/pubmed/31420371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-19-0756
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados